As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Soleno Therapeutics, Inc. The largest reported stake is BlackRock, Inc.'s, at 6.9%. 26 filings are on record since July 17, 2025 (Schedule 13G/A, April 24, 2026).
Sell to companies like Soleno Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Wellington Management Group LLP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-13
- · Holder: T. Rowe Price Associates, Inc. · Percent: 2% · SCHEDULE 13G/A
- · Holder: Wellington Management Group LLP · Percent: 8.6% · SCHEDULE 13G/A
- · Holder: Avoro Capital Advisors LLC · Percent: 4.45% · SCHEDULE 13G/A
- · Holder: State Street Corporation · Percent: 5.2% · SCHEDULE 13G
Soleno Therapeutics, Inc. has 26 Schedule 13D or 13G filings on record since 2025-07-17. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 6.9% | 3,543,296 | SCHEDULE 13G/A, 2026-04-24 | 2026-03-31 |
| State Street Corporation | 5.2% | 2,680,802 | SCHEDULE 13G, 2026-05-12 | 2026-03-31 |
| Avoro Capital Advisors LLC | 4.45% | 2,300,000 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Vivo Opportunity Fund Holdings, L.P. | 4.2% | 2,251,160 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Adage Capital Management, L.P. | 2.64% | 1,401,576 | SCHEDULE 13G/A, 2025-11-13 | 2025-09-30 |
| Janus Henderson Group Plc | 2.3% | 1,205,303 | SCHEDULE 13G/A, 2026-05-07 | 2026-04-30 |
| T. Rowe Price Associates, Inc. | 2% | 1,025,868 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Nantahala Capital Management, LLC | 1.99% | 1,001,350 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Fmr LLC | 0.4% | 193,014 | SCHEDULE 13G/A, 2026-05-07 | 2026-04-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
| Wellington Management Group LLP | 0% | 0 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
Holding shares or following this stake? See who's behind Soleno Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Soleno Therapeutics, Inc. and the records around it.
Soleno Therapeutics, Inc. elsewhere on the record
- Acquisition May 2026
- Who owns it
Companies that share a holder
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
- Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Compass Therapeutics, Inc. (Aug 2026)
- Nantahala Capital Management, LLC also filed stake reports on 70 other companies: Research Alliance Corp III (Oct 2026), ADC Therapeutics SA (Aug 2026), Anteris Technologies Global Corp. (Aug 2026)
Watch Soleno Therapeutics, Inc.
Get an email when Soleno Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Soleno Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Soleno Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Soleno Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
27 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Wellington Management Group LLP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Wellington Group Holdings LLP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Wellington Investment Advisors Holdings LLP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
The latest filing identifies Soleno Therapeutics, Inc. by CUSIP 834203309 and gives its principal executive office as 100 Marine Parkway, Suite 400, Redwood City (SCHEDULE 13G/A, 2026-08-13).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 5.5% | SCHEDULE 13G |
| 2025-08-06 | Fmr LLC | 6.6% | SCHEDULE 13G |
| 2025-08-07 | Fmr LLC | 15% | SCHEDULE 13G/A |
| 2025-08-12 | Adage Capital Management, L.P. | 7.1% | SCHEDULE 13G/A |
| 2025-08-12 | Vivo Opportunity Fund Holdings, L.P. | 7.4% | SCHEDULE 13G/A |
| 2025-08-14 | T. Rowe Price Associates, Inc. | 6.9% | SCHEDULE 13G/A |
| 2025-08-14 | Avoro Capital Advisors LLC | 4.1% | SCHEDULE 13G/A |
| 2025-08-14 | Nantahala Capital Management, LLC | 1.99% | SCHEDULE 13G/A |
| 2025-08-14 | Janus Henderson Group Plc | 10.5% | SCHEDULE 13G/A |
| 2025-10-31 | The Vanguard Group | 5.28% | SCHEDULE 13G |
| 2025-11-13 | Adage Capital Management, L.P. | 2.64% | SCHEDULE 13G/A |
| 2025-11-14 | Vivo Opportunity Fund Holdings, L.P. | 4.2% | SCHEDULE 13G/A |
| 2025-11-14 | Janus Henderson Group Plc | 11.4% | SCHEDULE 13G/A |
| 2026-02-10 | Wellington Management Group LLP | 6.2% | SCHEDULE 13G |
| 2026-02-17 | Avoro Capital Advisors LLC | 5.4% | SCHEDULE 13G |
| 2026-02-17 | Janus Henderson Group Plc | 13.4% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-24 | BlackRock, Inc. | 6.9% | SCHEDULE 13G/A |
| 2026-05-06 | Fmr LLC | 11.2% | SCHEDULE 13G/A |
| 2026-05-07 | Fmr LLC | 0.4% | SCHEDULE 13G/A |
| 2026-05-07 | Janus Henderson Group Plc | 2.3% | SCHEDULE 13G/A |
| 2026-05-12 | State Street Corporation | 5.2% | SCHEDULE 13G |
| 2026-05-15 | T. Rowe Price Associates, Inc. | 2% | SCHEDULE 13G/A |
| 2026-05-15 | Wellington Management Group LLP | 8.6% | SCHEDULE 13G/A |
| 2026-05-15 | Avoro Capital Advisors LLC | 4.45% | SCHEDULE 13G/A |
| 2026-08-13 | Wellington Management Group LLP | 0% | SCHEDULE 13G/A |
Questions about who owns Soleno Therapeutics, Inc.
Who owns Soleno Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Soleno Therapeutics, Inc.: BlackRock, Inc. (6.9%, Schedule 13G/A, filed 2026-04-24) and State Street Corporation (5.2%, Schedule 13G, filed 2026-05-12).
Who are the largest shareholders of Soleno Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Soleno Therapeutics, Inc. on this page are BlackRock, Inc. (6.9%) and State Street Corporation (5.2%).
When did BlackRock, Inc. buy into Soleno Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from BlackRock, Inc. on this page is the Schedule 13G, filed 2025-07-17, reporting 5.5%; its latest, Schedule 13G/A filed 2026-04-24, reports 6.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 26 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Soleno Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 18, 2026 | Acquired by Neurocrine Biosciences, Inc. | — | Acquisition | Source |
| May 18, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Soleno Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.